Severe Gout During Arsenic Therapy: Insights on Oxidative Stress and Interleukin‐1β in Gout
ACR Open Rheumatology · 2026-02 · 8 (2)
DOI: 10.1002/acr2.70119 ↗Kurz gefasst
Fallbericht in der Zeitschrift ACR Open Rheumatology, online erschienen am 10.02.2026. Verfasst von Jennie Hamilton und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
We report a 49‐year‐old male patient with a normal serum uric acid and recent diagnosis of acute promyelocytic leukemia (APL) who developed a severe polyarticular gout flare during treatment with arsenic trioxide (ATO). Unlike conventional chemotherapies, ATO acts through the generation of reactive oxygen species (ROS), leading to APL cell apoptosis. The gout flare in our patient was initially treated with high‐dose intravenous glucocorticoids with no clinical response and was subsequently treated with interleukin‐1β receptor blockade, which resulted in complete clinical resolution of his gout. Our case offers insights into inflammatory pathways in gout, including the evolving role of ROS in autoinflammation.
Autor:innen und Institutionen
- University of Alabama at Birmingham.
ORCID-Profile: Amanda Alexander
Zitieren
APA
Hamilton, J., & Alexander, A. (2026). Severe Gout During Arsenic Therapy: Insights on Oxidative Stress and Interleukin‐1β in Gout. ACR Open Rheumatology, 8(2). https://doi.org/10.1002/acr2.70119
Vancouver
Hamilton J, Alexander A. Severe Gout During Arsenic Therapy: Insights on Oxidative Stress and Interleukin‐1β in Gout. ACR Open Rheumatology. 2026;8(2). doi:10.1002/acr2.70119
BibTeX
@article{Hamilton2026,
author = {Hamilton, Jennie and Alexander, Amanda},
title = {Severe Gout During Arsenic Therapy: Insights on Oxidative Stress and Interleukin‐1β in Gout},
journal = {ACR Open Rheumatology},
year = {2026},
volume = {8},
number = {2},
doi = {10.1002/acr2.70119}
}
EUVIMED